Tier 2 — strong

The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial

Zohreh Sajadi Hezaveh, Azita Azarkeivan, Leila Janani, Sharieh Hosseini, Farzad Shidfar
Complementary therapies in medicine 2019 46:24-28

Bibliography

PubMed
PMID 31519283
DOI
10.1016/j.ctim.2019.02.017
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample84 adults with beta-thalassemia; 42 per group
InterventionQuercetin 500 mg/day versus starch placebo
Duration12 weeks
EndpointsInflammatory measures; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2019, this source examined inflammation and clinical symptoms. Design: Randomized double-blind placebo-controlled trial. Sample/model: 84 adults with beta-thalassemia; 42 per group. The exposure or intervention was Quercetin 500 mg/day versus starch placebo. Follow-up or treatment period: 12 weeks.

Iron, ferritin, transferrin saturation and hs-CRP fell versus placebo; TNF-alpha and total iron-binding capacity did not differ.

Disease-specific iron-overload study. Related liver-outcome reporting may share the cohort, and findings do not apply to iron-deficient people.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Iron, ferritin, transferrin saturation and hs-CRP fell versus placebo; TNF-alpha and total iron-binding capacity did not differ.
  • The recorded outcome domains were Inflammatory measures; Protein activity, binding or signaling.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus starch placebo; 12 weeks.

What this study can and cannot tell us

  • Disease-specific iron-overload study. Related liver-outcome reporting may share the cohort, and findings do not apply to iron-deficient people.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study
Eman Mohamed Elmokadem et al. · Drug design, development and therapy · 2025
Tier 2
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study
Italo Corsale et al. · International journal of colorectal disease · 2018
Tier 2
The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial
Fatemeh Javadi et al. · Journal of the American College of Nutrition · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology